Close Menu

This article has been updated to correctly represent the interim survival analysis for patients who cleared ctDNA at any point after treatment. 

NEW YORK – Researchers have demonstrated in a Phase II study that customized circulating tumor DNA (ctDNA) assays designed by genetic testing firm Natera could potentially be useful for monitoring whether patients with a variety of cancers will respond to immunotherapy.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Dec
15
Sponsored by
UgenTec

Diverse components of the UC Davis campus have been mobilized to deploy HTP testing to provide a safe working environment and keep the pandemic under control.